Literature DB >> 18951537

UPDRS activity of daily living score as a marker of Parkinson's disease progression.

Madaline B Harrison1, Scott A Wylie, Robert C Frysinger, James T Patrie, Diane S Huss, Lillian J Currie, G Frederick Wooten.   

Abstract

The activities of daily living (ADL) subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) captures the impact of Parkinson's disease (PD) on daily function and may be less affected than other subsections by variability associated with drug cycle and motor fluctuations. We examined UPDRS mentation, ADL and motor subscores in 888 patients with idiopathic PD. Multiple linear regression analyses determined the association between disease duration and UPDRS subscores as a function of medication status at examination and in a subset of patients with multiple examinations. Independent of medication status and across cross-sectional and longitudinal analyses, ADL subscores showed a stronger and more stable association with disease duration than other UPDRS subscores after adjusting for age of disease onset. The association between disease duration and the motor subscore depended on medication status. The strong association between ADL subscore and disease duration in PD suggests that this measure may serve as a better marker of disease progression than signs and symptoms assessed in other UPDRS sections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18951537      PMCID: PMC3103833          DOI: 10.1002/mds.22335

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.

Authors:  M A Hely; J G Morris; R Traficante; W G Reid; D J O'Sullivan; P M Williamson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Progression of parkinsonian signs in Parkinson disease.

Authors:  E D Louis; M X Tang; L Cote; B Alfaro; H Mejia; K Marder
Journal:  Arch Neurol       Date:  1999-03

3.  Functional decline in Parkinson disease.

Authors:  J Jankovic; A S Kapadia
Journal:  Arch Neurol       Date:  2001-10

4.  Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease.

Authors:  Christopher G Goetz; Sue Leurgans; Rema Raman
Journal:  Mov Disord       Date:  2002-03       Impact factor: 10.338

5.  Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination section.

Authors:  G T Stebbins; C G Goetz
Journal:  Mov Disord       Date:  1998-07       Impact factor: 10.338

6.  Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale.

Authors:  E D Louis; T Lynch; K Marder; S Fahn
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

7.  Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group.

Authors:  P Martínez-Martín; A Gil-Nagel; L M Gracia; J B Gómez; J Martínez-Sarriés; F Bermejo
Journal:  Mov Disord       Date:  1994-01       Impact factor: 10.338

  7 in total
  28 in total

1.  Can focusing on UPDRS Part II make assessments of Parkinson disease progression more efficient?

Authors:  Cristina Sampaio
Journal:  Nat Clin Pract Neurol       Date:  2009-03

2.  Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis.

Authors:  Ping Liu; Tao Feng; Yong-jun Wang; Xuan Zhang; Biao Chen
Journal:  J Zhejiang Univ Sci B       Date:  2011-09       Impact factor: 3.066

3.  Randomized trial of care management to improve Parkinson disease care quality.

Authors:  Karen I Connor; Eric M Cheng; Frances Barry; Hilary C Siebens; Martin L Lee; David A Ganz; Brian S Mittman; Megan K Connor; Lisa K Edwards; Michael G McGowan; Barbara G Vickrey
Journal:  Neurology       Date:  2019-03-22       Impact factor: 9.910

4.  The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson's disease: preliminary observations.

Authors:  Branislav Veselý; Eva Koriťáková; Nicolaas I Bohnen; Daša Viszlayová; Silvia Királová; Peter Valkovič; Egon Kurča; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2019-07-22       Impact factor: 3.575

5.  Remedial effects of motivational incentive on declining cognitive control in healthy aging and Parkinson's disease.

Authors:  Helga A Harsay; Jessika I V Buitenweg; Jasper G Wijnen; Maria J S Guerreiro; K Richard Ridderinkhof
Journal:  Front Aging Neurosci       Date:  2010-10-15       Impact factor: 5.750

6.  Outcome measures for Parkinson's disease dementia: a systematic review.

Authors:  Samantha K Holden; Wallace E Jones; Keith A Baker; Isabel M Boersma; Benzi M Kluger
Journal:  Mov Disord Clin Pract       Date:  2015-09-16

7.  Quantitative susceptibility mapping of the midbrain in Parkinson's disease.

Authors:  Guangwei Du; Tian Liu; Mechelle M Lewis; Lan Kong; Yi Wang; James Connor; Richard B Mailman; Xuemei Huang
Journal:  Mov Disord       Date:  2015-09-12       Impact factor: 10.338

8.  Effects of Group, Individual, and Home Exercise in Persons With Parkinson Disease: A Randomized Clinical Trial.

Authors:  Laurie A King; Jennifer Wilhelm; Yiyi Chen; Ron Blehm; John Nutt; Zunqiu Chen; Andrea Serdar; Fay B Horak
Journal:  J Neurol Phys Ther       Date:  2015-10       Impact factor: 3.649

9.  Nigrostriatal and Mesolimbic D2/3 Receptor Expression in Parkinson's Disease Patients with Compulsive Reward-Driven Behaviors.

Authors:  Adam J Stark; Christopher T Smith; Ya-Chen Lin; Kalen J Petersen; Paula Trujillo; Nelleke C van Wouwe; Hakmook Kang; Manus J Donahue; Robert M Kessler; David H Zald; Daniel O Claassen
Journal:  J Neurosci       Date:  2018-02-26       Impact factor: 6.167

10.  Validation and cross-cultural adaptation of the Self-Assessment Disability Scale in patients with Parkinson's disease in Serbia.

Authors:  Tatjana Gazibara; Iva Stankovic; Aleksandra Tomic; Marina Svetel; Darija Kisic Tepavcevic; Vladimir S Kostic; Tatjana Pekmezovic
Journal:  J Neurol       Date:  2013-04-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.